Propagation and Maintenance of Cancer Stem Cells: A Major Influence of the Long Non-Coding RNA H19

Lecerf, Clément; Peperstraete, Evodie; Bourhis, Xuefen Le; Adriaenssens, Éric

doi:10.3390/cells9122613

Cited by 15 publications

(10 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long non-coding RNAs (lncRNAs) are a heterogeneous class of transcripts longer than 200 nucleotides with limited protein-coding potential [158,159]. CAFs were shown to transfer lncRNA H19 to neighboring colorectal cancer cells [151,[160][161][162] and promote the stemness via activating Wnt/β-catenin signaling causing resistance to oxaliplatin-mediated apoptosis [163]. Exosomal lncRNA enhance invasion, migration, proliferation and inhibit apoptosis in cervical cancer cells and in NSCLC [164,165].…”

Section: Caf-derived Extracellular Vesiclesmentioning

confidence: 99%

Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance

Neophytou

Trougakos

Erin

et al. 2021

Cancers

140

View full text Add to dashboard Cite

The ability of tumor cells to evade apoptosis is established as one of the hallmarks of cancer. The deregulation of apoptotic pathways conveys a survival advantage enabling cancer cells to develop multi-drug resistance (MDR), a complex tumor phenotype referring to concurrent resistance toward agents with different function and/or structure. Proteins implicated in the intrinsic pathway of apoptosis, including the Bcl-2 superfamily and Inhibitors of Apoptosis (IAP) family members, as well as their regulator, tumor suppressor p53, have been implicated in the development of MDR in many cancer types. The PI3K/AKT pathway is pivotal in promoting survival and proliferation and is often overactive in MDR tumors. In addition, the tumor microenvironment, particularly factors secreted by cancer-associated fibroblasts, can inhibit apoptosis in cancer cells and reduce the effectiveness of different anti-cancer drugs. In this review, we describe the main alterations that occur in apoptosis-and related pathways to promote MDR. We also summarize the main therapeutic approaches against resistant tumors, including agents targeting Bcl-2 family members, small molecule inhibitors against IAPs or AKT and agents of natural origin that may be used as monotherapy or in combination with conventional therapeutics. Finally, we highlight the potential of therapeutic exploitation of epigenetic modifications to reverse the MDR phenotype.

show abstract

Section: Caf-derived Extracellular Vesiclesmentioning

confidence: 99%

Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance

Neophytou

Trougakos

Erin

et al. 2021

Cancers

140

View full text Add to dashboard Cite

show abstract

“…Furthermore, in colorectal cancer, the lncTCF7 interacts with subunits of the SWI/SNF chromatin remodeling complex, regulating the transcription of the TCF7 gene and activating the Wnt cascade, involved in stem cell self-renewal ( 229 ). H19 is another lncRNA overexpressed in many cancers and confer stem-like properties in correlation with stem cell markers like SOX2, OCT4, NOTCH1, c-Myc, and ABCG2 ( 230 – 232 ).…”

Section: Lncrnas In Drug Resistance Mechanismsmentioning

confidence: 99%

Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma

et al. 2022

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) originates in the squamous cell lining the mucosal surfaces of the head and neck region, including the oral cavity, nasopharynx, tonsils, oropharynx, larynx, and hypopharynx. The heterogeneity, anatomical, and functional characteristics of the patient make the HNSCC a complex and difficult-to-treat disease, leading to a poor survival rate and a decreased quality of life due to the loss of important physiologic functions and aggressive surgical injury. Alteration of driver-oncogenic and tumor-suppressing lncRNAs has recently been recently in HNSCC to obtain possible biomarkers for diagnostic, prognostic, and therapeutic approaches. This review provides current knowledge about the implication of lncRNAs in drug resistance mechanisms in HNSCC. Chemotherapy resistance is a major therapeutic challenge in HNSCC in which lncRNAs are implicated. Lately, it has been shown that lncRNAs involved in autophagy induced by chemotherapy and epithelial–mesenchymal transition (EMT) can act as mechanisms of resistance to anticancer drugs. Conversely, lncRNAs involved in mesenchymal–epithelial transition (MET) are related to chemosensitivity and inhibition of invasiveness of drug-resistant cells. In this regard, long non-coding RNAs (lncRNAs) play a pivotal role in both processes and are important for cancer detection, progression, diagnosis, therapy response, and prognostic values. As the involvement of more lncRNAs is elucidated in chemoresistance mechanisms, an improvement in diagnostic and prognostic tools could promote an advance in targeted and specific therapies in precision oncology.

show abstract

“…They have both multicellular differentiation potential and self-renewal ability. CSCs reprogram relevant cells in the tumor microenvironment to favor tumor development while suppressing the tumor-killing effect of immune cells (109,110). Chen et al found that targeting CMTM6 suppresses stem cell-like properties in HNSCC (18).…”

Section: Cmtm6 and Cmtm4 Maintain The Cancer Stem Cell Phenotypesmentioning

confidence: 99%

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment

Zhang

Dai

2022

Front. Immunol.

View full text Add to dashboard Cite

The tumor microenvironment (TME) plays crucial roles in regulating tumor occurrence, progress, metastasis and drug resistance. However, it remains largely elusive how the components of TME are regulated to govern its functions in tumor biology. Here, we discussed how the two novel functional proteins, chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing 6 (CMTM6) and CMTM4, which involved in the post-translational regulation of PD-L1, modulate the TME functions. The roles of CMTM6 and CMTM4 in regulating TME components, including immune cells and tumor cells themselves were discussed in this review. The potential clinical applications of CMTM6 and CMTM4 as biomarkers to predict therapy efficacy and as new or combined immunotherapy targets are also highlighted. Finally, the current hot topics for the biological function of CMTM6/4 and several significant research directions for CMTM6/4 are also briefly summarized in the review.

show abstract

Propagation and Maintenance of Cancer Stem Cells: A Major Influence of the Long Non-Coding RNA H19

Cited by 15 publications

References 103 publications

Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance

Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance

Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment

Contact Info

Product

Resources

About